{"ok":true,"trend":{"id":893932,"platform":"news","region":"global","key":"yan leyfman: real-world outcomes after first-line osimertinib in egfr-mutant nsclc","title":"Yan Leyfman: Real-World Outcomes After First-Line Osimertinib in EGFR-Mutant NSCLC","url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5HVkRIekxTRGY5X2t4dXF2SGRnNVUxYTIzaUJfanFNU2NvVjJmZy1YRmtSZno3b0EySnV3YU5oUUdhMWdYa3NzYTBkRWFlN1htbHJpZ3ZSN3pKUmpJMHFyWDhJUVpVTmE1bUFEaw?oc=5","first_seen":"2026-10-03T19:09:21.853334Z","last_seen":"2026-10-03T23:17:16.522878Z","last_rank":33,"peak_rank":21,"last_volume":null,"peak_volume":0,"seen_count":4,"score":0.76875,"category_hint":"science","section":"science","category":"science","summary":"Oncologist and researcher Yan Leyfman reported real-world data on outcomes after first-line osimertinib treatment in patients with EGFR-mutated non-small cell lung cancer. The presentation highlights how the targeted therapy performs outside clinical trial settings, a topic of interest to oncologists tracking effectiveness and resistance patterns in routine care.","why":"Oncology specialists are following new real-world evidence on osimertinib, the standard first-line therapy for EGFR-mutated lung cancer.","tone":"neutral","entities":["Yan Leyfman","osimertinib","EGFR-mutated NSCLC"],"summarized_at":"2026-10-04T01:18:55.180918Z","meta":{"via":"scan","lang":"en","term":"science","source":"Oncodaily","published":"Sat, 03 Oct 2026 18:42:36 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Yan Leyfman Presents Real-World Osimertinib Outcomes in EGFR-Mutant Lung Cancer","section_name":"Science","category_name":"Science","timeline":[{"captured_at":"2026-10-03T19:09:21.853334Z","rank":21,"volume":null},{"captured_at":"2026-10-03T20:32:26.603973Z","rank":24,"volume":null},{"captured_at":"2026-10-03T21:55:10.917663Z","rank":30,"volume":null},{"captured_at":"2026-10-03T23:17:16.522878Z","rank":33,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5HVkRIekxTRGY5X2t4dXF2SGRnNVUxYTIzaUJfanFNU2NvVjJmZy1YRmtSZno3b0EySnV3YU5oUUdhMWdYa3NzYTBkRWFlN1htbHJpZ3ZSN3pKUmpJMHFyWDhJUVpVTmE1bUFEaw?oc=5","author":"Oncodaily","title":"Yan Leyfman: Real-World Outcomes After First-Line Osimertinib in EGFR-Mutant NSCLC","snippet":null,"posted_at":"2026-10-03T18:42:36Z","likes":null}],"elsewhere":[],"window":"7d"}}